June 2022 - Pharmaceutical Market Europe

June 2022 - Pharmaceutical Market Europe
Published on 16 June 2022

Description:

A creative awakening – bringing innovation to patients; Parkinson’s disease and the microbiome; Rare diseases – changing the standard of care

Preview:

36 articles from this collection:
PME April 2022
PME April 2022
2 - HANOVER
2 - HANOVER
3 - Comment
3 - Comment
4 - T40
4 - T40
5 - Contents
5 - Contents
6-7 - News
6-7 - News
6-7 - PME - Pharma Market Europe Pharmaceutical News
8-9 - News
8-9 - News
10 - Coronavirus news
10 - Coronavirus news
11 - TL Langland - Realising the potential of omnichannel in medical communications
11 - TL Langland - Realising the potential of omnichannel in medical communications
12 - DARWIN'S MEDICINE - Dumbing down – why your company  may be making you less competent
12 - DARWIN'S MEDICINE - Dumbing down – why your company may be making you less competent
12 - Pharma Market Europe Darwin’s medicine
13 - POLICY AND PUBLIC HEALTH - One in three hundred
13 - POLICY AND PUBLIC HEALTH - One in three hundred
The technology responses to this pandemic have fallen far short of expectations
14 - MIKE DIXON - Braveheart – the importance of allowing ourselves to be truly innovative
14 - MIKE DIXON - Braveheart – the importance of allowing ourselves to be truly innovative
15 - PHARMA MARKETERS’ BLOG - Be prepared!
15 - PHARMA MARKETERS’ BLOG - Be prepared!
16-17 - TAKEDA'S PETER SCHNACK - Digital fuel – driving innovation and improving patient outcomes
16-17 - TAKEDA'S PETER SCHNACK - Digital fuel – driving innovation and improving patient outcomes
18 - TL OLOGY - Delivering content to fuel omnichannel engagement
18 - TL OLOGY - Delivering content to fuel omnichannel engagement
19 - TL Bedrock - How understanding the rare disease patient’s lived experience creates better health communications
19 - TL Bedrock - How understanding the rare disease patient’s lived experience creates better health communications
20-21 - TL HANOVER - The microbiome as a drug target for Parkinson’s disease
20-21 - TL HANOVER - The microbiome as a drug target for Parkinson’s disease
22-23 - Rare disease: Redefining how pharma looks at rare diseases
22-23 - Rare disease: Redefining how pharma looks at rare diseases
24-25 -  COVID-19 VACCINE SIDE EFFECTS - A community study on COVID-19 vaccine side effects
24-25 - COVID-19 VACCINE SIDE EFFECTS - A community study on COVID-19 vaccine side effects
26 - TL DNA - How pharma found its voice – health communications for a brave new world
26 - TL DNA - How pharma found its voice – health communications for a brave new world
27 - TL EARTHWARE - The pharma dichotomy
27 - TL EARTHWARE - The pharma dichotomy
28-29 - DIGITAL CHANNELS AND HCPS - Closing the widening gap between HCPs’ expectations and their pharma experiences
28-29 - DIGITAL CHANNELS AND HCPS - Closing the widening gap between HCPs’ expectations and their pharma experiences
30-32 - INNOVATION AND CREATIVITY IN HEALTHCARE - Communications excellence
30-32 - INNOVATION AND CREATIVITY IN HEALTHCARE - Communications excellence
33 - TL ASHFIELD - Bringing clarity to the complex: improving communication approaches in a data-rich world
33 - TL ASHFIELD - Bringing clarity to the complex: improving communication approaches in a data-rich world
34 - TL RESONANT - How Resonant’s innovation and creativity resolve healthcare communications challenges
34 - TL RESONANT - How Resonant’s innovation and creativity resolve healthcare communications challenges
35 - TL COUCH - The importance of beliefs in creative health engagement
35 - TL COUCH - The importance of beliefs in creative health engagement
36 - TL PURPLE AGENCY - ‘The man behind the mouse’: bringing courage to creativity in healthcare communications
36 - TL PURPLE AGENCY - ‘The man behind the mouse’: bringing courage to creativity in healthcare communications
37 - PMGROUP - Webinars
37 - PMGROUP - Webinars
38-39 - HEALTHCARE INNOVATION: Redefining how pharma looks at rare diseases
38-39 - HEALTHCARE INNOVATION: Redefining how pharma looks at rare diseases
40 - TL ASHFIELD - Collaborating to define patient-centred PROs for mutual benefit
40 - TL ASHFIELD - Collaborating to define patient-centred PROs for mutual benefit
41 - FLYPHARMA
41 - FLYPHARMA
42-44 - Appointments
42-44 - Appointments
45 -  HEALTHCARE COMMS
45 - HEALTHCARE COMMS
46 - PM Society Digital Awards
46 - PM Society Digital Awards
47 - Recruitment
47 - Recruitment
43 - Pharma Market Europe (PME) Recruitment
48 - T40
48 - T40